Business
Oxford and AstraZeneca resume UK coronavirus vaccine trial – ABC News
Regulators give researchers the green light to continue a study that was suspended when a patient in the UK reportedly suffered a side-effect.
Oxford University has announced it will resume a trial for a coronavirus vaccine it is developing with pharmaceutical company AstraZeneca after getting the green light from safety watchdogs.
Key points:
- Globally some 18,000 people have received the trial vaccine
- The vaccine was in late-stage clinical trials in the US, Britain, Brazil and South Africa
- The US was aiming for fast-track approval of a vaccine before November’s presidential election
The late-stage …
Continue Reading
-
Business14 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business10 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General20 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Noosa News10 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred